O not grow to be comparable to guys. J Hypertens 2008, 26:1983?992. 30. Toth MJ, Tchernof A, Websites CK, Poehlman ET: Impact of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000, 24:226?31. 31. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR: Cardiovascular illness in the diabetic woman. J Clin Endocrinol Metab 1999, 84:1835?838. 32. Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD: Variety II diabetes abrogates sex variations in endothelial function in premenopausal girls. Circulation 2000, 101:2040?046. 33. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with variety two diabetes and in nondiabetic subjects with and with out prior myocardial infarction. N Engl J Med 1998, 339:229?34. 34. Eckel RH, Kahn R, Robertson RM, Rizza RA: Stopping cardiovascular disease and diabetes: a contact to action in the American Diabetes Association and also the American Heart Association. Diabetes Care 2006, 29:1697?699. 35. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger danger element for fatal ischemic heart illness in ladies than in men? The Rancho Bernardo Study. JAMA 1991, 265:627?31. 36. Zhang L, Qiao Q, Tuomilehto J, Hammar N, Ruotolo G, Stehouwer CD, Heine RJ, Eliasson M, Zethelius B, DECODE Study Group: The effect of dyslipidaemia on cardiovascular mortality in individuals with out a prior history of diabetes inside the DECODE Study. Atherosclerosis 2009, 206(1):298?02. 37. Pollex RL, Joy TR, Hegele RA: Emerging antidyslipidemic drugs. Specialist Opin Emerg Drugs 2008, 13(2):363?81. 38. Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and form two diabetes: therapeutic choices beyond statins.195387-29-2 supplier Cardiovasc Diabetol 2006, five:20.6-Bromothiazolo[4,5-b]pyridin-2-amine Price 39.PMID:23537004 Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA: The value of recognizing and treating low levels of high-density lipoprotein cholesterol: a brand new era in atherosclerosis management. Rev Cardiovasc Med 2008, 9(4):239?58. 40. Sharma RK, Singh VN, Reddy HK: Pondering beyond low-density lipoprotein cholesterol: techniques to additional minimize cardiovascular threat. Vasc Health Risk Manag 2009, 5:793?99. 41. Calle MC, Fernandez ML: Inflammation and type 2 diabetes. Diabetes Metab 2012, 38(three):183?91. 42. Miazgowski T, Noworyta-Zietara M, Safranow K, Ziemak J, Widecka K: Serum adiponectin, bone mineral density and bone turnover markers in postmenopausal females with newly diagnosed Variety two diabetes: a 12-month follow-up. Diabet Med 2012, 29:62?9. 43. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N: Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences within a Japanese community-dwelling population. Cardiovasc Diabetol 2011, 10:51.Mascarenhas-Melo et al. Cardiovascular Diabetology 2013, 12:61 http://cardiab/content/12/1/Page 14 of44. Goodarzi MT, Babaahmadi-Rezaei H, Kadkhodaei-Eliaderani M, Haddadinezhad S: Relationship of serum adiponectin with blood lipids, HbA(1)c, and hs-CRP in sort II diabetic postmenopausal girls. J Clin Lab Anal 2007, 21(3):197?00. 45. Rasul S, Ilhan A, Reiter MH, Baumgartner-Parzer S, Kautzky-Willer A: Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly kind two diabetic sufferers. Gend Med 2011, eight(two):93?02. 46. Shepherd J: Dyslipidaemia in diabetic patients: time for any rethink. Diabetes Obes.